Clinician's Roundtable

As fecal immunochemical testing (FIT) becomes more common in colorectal cancer screening, questions remain about post-FIT follow-up, especially when colonoscopies yield negative results. To explore this further, a recent review looked at the risk of colorectal cancer postcolonoscopy and analyzed the most common reasons it may occur. Hear Dr. Aasma Shaukat, a coauthor of the review, discuss the rationale behind it and its findings, which highlighted the importance of colonoscopy quality. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine and a Professor in the Department of Population Health at NYU Grossman School of Medicine. She also serves as the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU Langone Health.

Conflicting colorectal cancer screening (CRC) guidelines have sometimes led to confusion over optimal starting ages and strategies. Join Dr. Pedro Nascimento de Lima as he walks through a comprehensive modeling study that tested 26 different strategies over 4,000 scenarios to test how and when it is most effective to screen. Dr. Nascimento de Lima is an Engineer at RAND, a Professor at the RAND School of Public Policy, and an investigator with the colorectal modeling group of the Cancer Intervention and Surveillance Modeling Network.

Colorectal cancer is highly preventable, but many eligible patients remain unscreened due to common barriers and misconceptions. Tune in to hear Dr. Harish K. Gagneja share practical, patient-centered strategies to improve screening rates through education, choice, and reducing obstacles to care. Dr. Gagneja is a board-certified gastroenterologist in Austin, Texas.

Integrating colorectal cancer screening into OB/GYN care expands preventive services and supports comprehensive patient health. Tune in to hear Dr. Jemel Bingham discuss practical workflow strategies, EHR integration, and patient-centered approaches to streamline screening and follow-up care. Dr. Bingham is a board-certified OB/GYN at Hartford Hospital and other affiliated medical groups in Connecticut.

A recent study showed that tailored Spanish-language navigation paired with the multi-target stool DNA (mt-sDNA) test can significantly improve colorectal cancer re-screening adherence among Spanish-speaking patients. Hear Ryan Quigley speak with Dr. Mallik Greene, a coauthor of the study, about how these findings could shape the future of colorectal cancer screening in Spanish-speaking populations. Dr. Greene’s educational background includes a Bachelor’s degree in Pharmacy, a PhD and a Postdoctoral Fellowship in Health Economics and Outcomes Research, and a Doctorate in Business Administration.

New evidence from a report published in Gastroenterology demonstrates that higher adenoma detection rates (ADR) are directly associated with improved colorectal cancer detection, reinforcing ADR as a critical quality metric. Learn more about this study and its implications for optimizing screening quality and reducing missed cancers with Dr. Brian McDonough and Dr. Renee Williams, Professor of Medicine and Associate Chair for Health Equity at the NYU Grossman School of Medicine.

How do lived experience, community dynamics, and socioeconomic realities shape infectious disease risk and patient decision making? Dr. Darilyn Moyer, Executive Vice President and Chief Executive Officer of the American College of Physicians, explains how incorporating patient context into communication and care strategies can help us better address infectious disease threats like COVID-19.

Emerging research is redefining the role of the gut microbiome in food allergy and immune tolerance. Here to share some of the most groundbreaking findings is Dr. Mustafa Ozcam. He discusses how gut microbes metabolize allergenic proteins, shape immune development, and serve as potential biomarkers to predict oral immunotherapy success in food allergy patients. Dr. Ozcam is an Assistant Professor of Microbiology and Immunology at the University of Maryland School of Medicine, and he spoke about this topic at the 2026 American Academy of Allergy, Asthma, and Immunology Annual Meeting.

Financial and space limitations are two of the most pressing issues facing allergists and immunologists in academic practice. Fortunately, negotiation principles, like BATNA and ZOPA, and disruptive innovation tactics can help address these common issues. To learn more, we recently spoke with Dr. Marcus Shaker. Not only is he a Professor of Pediatrics and Medicine at the Dartmouth Geisel School of Medicine in New Hampshire, but he also spoke about this topic at the 2026 American Academy of Allergy, Asthma, & Immunology Annual Meeting.

Given that severe asthma management is entering a new era of biologically driven precision, Dr. Sally Wenzel joins us to discuss the complexity within Type 2 inflammation and the limitations of relying on a single biomarker assessment. She also differentiates childhood-onset allergic asthma from adult-onset disease, underscoring how age of onset—along with underlying biology—can inform therapeutic strategy. Dr. Wenzel serves as the Director of the Asthma Institute at UPMC, and she spoke about this topic at the 2026 American Academy of Allergy, Asthma, and Immunology Annual Meeting.